



Embargoed until Friday, June 20, 2025 at 12:45 PM CT

The American Diabetes Association Demonstrates Its Commitment to Curbing the Obesity Epidemic with Obesity Standards of Care

Symposium previews new content for Standards of Care in Overweight and Obesity, designed to improve patient care and outcomes

CHICAGO, **IL**. (June 20, 2025) - Recent developments for the new *Standards of Care in Overweight and Obesity* guidelines, the first clinical guidance of its kind, were presented during the **Standards of Care in Overweight and Obesity 2025 Updates symposium** at the 85th Scientific Sessions of the American Diabetes Association[®] (ADA) in Chicago.

The Obesity Association[™], a division of the ADA, recently announced the publication of *Weight Stigma and Bias*: Standards of Care in Overweight and Obesity—2025, along with the Introduction & Methodology section in *BMJ Open Diabetes Research & Care*. This comes at a time when about 110 million American adults are impacted by obesity. Further, up to (53%) of new cases of type 2 diabetes are attributed to obesity every year, demonstrating the need for comprehensive, evidence-based guidelines to inform care.

The symposium highlighted key insights on physician guidelines for weight stigma and bias, including training for health care professionals, creating inclusive clinical environments, person-centered communication, shared decision making, and evidence-based interventions. Additionally, researchers highlighted what is next for the clinical guidelines, including a potential section for pharmacologic treatment and a preview of what is going to be covered in that section.

The Standards of Care in Overweight and Obesity 2025 Updates symposium is one of many obesity-related symposia and abstracts at the 85th Scientific Sessions, spanning basic through clinical and implementation science. Additional studies highlighting groundbreaking developments obesity treatment and care to be presented at ADA's annual meeting include:

 Once-Monthly MariTide for the Treatment of Obesity in People with or without Type 2 Diabetes—A 52-Week Phase 2 Study





- ADJUnct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) Trial Outcomes
- Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide
- PATHWEIGH Trial—Building the Highway for Weight Management in Primary Care
- First Report of a Phase 3 RCT of Orforglipron, a Small Nonpeptide GLP-1RA, as Monotherapy in Drug-Naïve Type 2 Diabetes with Inadequate Glycemic Control—The ACHIEVE-1 Trial
- Efficacy and Safety of CagriSema 2.4mg/2.4mg in Adults with Overweight/Obesity—The REDEFINE 1 and REDEFINE 2 Clinical Trials

"The ADA's *Standards of Care in Diabetes* guideline is the gold standard for diabetes care and management," said Raveendhara Bannuru, MD, PhD, the ADA's vice president, medical affairs and lead author of the guidelines. "The new *Standards of Care in Overweight and Obesity* guidelines stand to yield significant impact and progress in patient care, and it's only just the beginning."

As part of the ADA's ongoing commitment to combating obesity, new clinical practice guidelines and initiatives are continually being developed to advance the quality of care.

Research presentation details:

Dr. Bannuru and other Professional Practice Committee members will present these findings at the symposium:

- Standards of Care in Overweight and Obesity 2025 Updates
- Friday, June 20 from 12:45–1:45 p.m.

###

About the ADA's Scientific Sessions

The ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations





and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions.

About the Obesity Association

Obesity is an epidemic that demands both attention and action. The Obesity Association, a division of the American Diabetes Association, is dedicated to reducing the prevalence of obesity and improving health outcomes. Through a focus on education, action, and evidence-based support, we strive to create a world where people affected by obesity can thrive.

About the American Diabetes Association

The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes), Spanish Facebook (Association), and Instagram (@AmDiabetes Associatios). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (QAmDiabetes Associatios).